Navigation Links
NORTHWEST BIO Announces Positive Third Quarter Progress
Date:10/6/2011

BETHESDA, Md., Oct. 6, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it has exceeded its Q3 projection of 15 clinical trial sites by the end of the quarter, with 17 sites at major medical institutions across the U.S. now open and active where patients can enroll in the Company's ongoing clinical trial of DCVax® immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.  The Company likewise exceeded its Q2 projections, as previously announced.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The Company said it is continuing to add clinical trial sites in the U.S. and Europe.  The Company expects to have 25 sites open and active by the end of the next quarter (Q4), with further growth expected into 2012.  Open and active trial sites are listed on the U.S. Government's website, www.clinicaltrials.gov, and on NORTHWEST BIO's website www.nwbio.com  

The Company's clinical trial site expansion reflects growing interest from both physicians and patients, and a growing awareness of the positive data from the Company's prior clinical trials for GBM brain cancer.  In those trials, patients who received DCVax® showed a median survival of 3 years compared with median survival of 14.6 months for patients who receive standard of care (surgery, radiation and chemotherapy).  Patients who received DCVax® also experienced a substantially longer time to tumor recurrence: a median of 2 years, compared with 6.9 months in patients who received standard of care.  DCVax® was well-tolerated, with no toxic side effects.

NORTHWEST BIO's current clinical trial for GBM brain cancer also offers a key difference from other immune therapy trials currently under way. &#
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011
2. Family Foundation of Business Leader Invests $4.55 Million in Northwest Biotherapeutics for Promising Clinical Trials in the US and Europe
3. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
4. Dendreon CEO Dr. Mitchell Gold Named Ernst & Young Entrepreneur Of The Year® 2011 Pacific Northwest Award Winner
5. Northwest Biotherapeutics Announces Change and Expansion of Management Team
6. Northwest Biotherapeutics Announces Series of Financing Arrangements
7. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Northwest Biotherapeutics Addresses Recent Market Activity
10. Cell Therapeutics, Inc. (CTI) to Present at Life Science Innovation Northwest
11. Registration Open for WBBAs Life Science Innovation Northwest 2011 Event Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Crystal Diagnostics (CDx) Xpress ... it has received AOAC-PTM Certifications for the six non-O157 Shiga ... O145; collectively referred to as STEC or the “Big-6”) as ... forming unit (cfu) per 325 g of raw ground beef ...
(Date:1/22/2015)... zFlo Motion , a US leader ... exciting product from a new partner. STT-Systems has ... past 15 years, with offerings in the optical-motion capture, 3D ... system (inertial measurement unit), iSen, is opening eyes around the ...
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 23D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2
... of Roche Diagnostics, North America, Has 25 Years of Life ... Sciences Industry ... KOOL ), a leading supplier of innovative products that,process and store ... Chief Executive Officer, Roche Diagnostics,Corporation, North America, has been named to ...
... with Company Estimates Highlighted by 11% Discovery ... Products and Services Growth -, ... ) today reported second quarter financial,results for 2008. Revenues were $34.0 ... quarter of $35.3 million. Revenues were impacted,by a $3.5 million decline ...
... ISLAND, S.C., Aug. 6 Denham Capital,("Denham") ... to $60 million in VitAG,Corporation ("VitAG"). VitAG ... fertilizer product capable of competing with and,outperforming ... of multiple biosolids-to-fertilizer manufacturing plants., "Denham,s ...
Cached Biology Technology:ThermoGenesis Names Tiffany Olson to Board of Directors 2ThermoGenesis Names Tiffany Olson to Board of Directors 3Caliper Life Sciences Reports Second Quarter 2008 Results 2Caliper Life Sciences Reports Second Quarter 2008 Results 3Caliper Life Sciences Reports Second Quarter 2008 Results 4Caliper Life Sciences Reports Second Quarter 2008 Results 5Caliper Life Sciences Reports Second Quarter 2008 Results 6Caliper Life Sciences Reports Second Quarter 2008 Results 7Caliper Life Sciences Reports Second Quarter 2008 Results 8Caliper Life Sciences Reports Second Quarter 2008 Results 9Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids 2
(Date:1/22/2015)... YORK , Jan. 22, 2015   EyeLock, Inc. , ... it has appointed Steve Gerber to the new ... will be responsible for leading development of mobile platforms and ... years of success and innovation in the semiconductor industry to ...
(Date:12/22/2014)... 2014  The 2014 Holiday Season may be the brightest ... reports that the long anticipated floodgates for consumer biometrics ... for smart phones, tablets, and wearable mobile devices that ... billion users with nearly 4.8 billion biometric devices by ...
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... organic farming becomes more common, methods to identify ... a recent study in Journal of Environmental Quality, ... if non-organic, synthetic fertilizers were used on sweet ... de Investigacin y Desarrollo Agrario y Agrario y ...
... REM sleep deprivation procedure reduces cell proliferation in the ... of rats, according to a study published in the ... study, authored by Dennis McGinty, PhD, of the V.A. ... rats. REM sleep deprivation was achieved by a ...
... of Southern California have developed a prostate cancer vaccine ... of young mice genetically predestined to develop the disease. ... they suggest the same strategy might work for men ... potential diagnostic indicator of prostate cancer. By ...
Cached Biology News:Is it organic or not? 24 days of REM sleep deprivation contributes to a reduction of cell proliferation in rats 2Prostate cancer: Watchful wait or vaccinate? 2Prostate cancer: Watchful wait or vaccinate? 3
Rabbit Anti-conjugated Agmatine Polyclonal Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
Biology Products: